Wondering If You Carry BRCA? Here's What Your Genes Can Tell You.

BRCA1 is one of your body’s primary tumor suppressor genes. Its job is relentless: scan your cells for DNA damage, signal when something goes wrong, and trigger repair or cell death if the damage is too severe. When BRCA1 works as designed, it’s like having a security system that catches intruders before they breach the perimeter.

A BRCA1 mutation disrupts this surveillance system. Carriers have a 45-87% lifetime risk of developing breast cancer and 40-46% risk for ovarian cancer, compared to 12% and 1.3% in the general population. About 1 in 400 people carry a BRCA1 variant, though rates are higher in certain populations like Ashkenazi Jewish women. The mutation doesn’t guarantee cancer, but it dramatically shifts the odds.

For you, this means your cells are missing a critical checkpoint. Damage that should trigger repair or cell death instead gets copied and passed forward. Over time, this accumulation is how cancers develop. But knowing you carry BRCA1 means you can monitor aggressively, catch problems early, and make informed choices about prevention.

APOE is your brain’s logistics manager. It packages and transports cholesterol and lipids throughout your nervous system, maintaining neuronal health and clearance of metabolic waste. This becomes critical when misfolded proteins like amyloid start accumulating, a hallmark of Alzheimer’s disease. APOE is supposed to clear these toxic proteins. When it works well, your brain stays protected.

APOE comes in three common forms: E2, E3, and E4. If you carry the APOE4 allele, your risk of developing Alzheimer’s disease increases significantly; homozygous E4 carriers have up to 8-10 times higher lifetime risk compared to E3/E3 carriers. Roughly 25-30% of the population carries at least one E4 copy. The E4 variant is less efficient at clearing amyloid, allowing it to accumulate in the brain.

You experience this as cognitive changes that might feel like normal aging at first. Memory slips. Brain fog that won’t clear. Processing that feels slower. If you carry E4, these early signals matter more because they’re amplified risk, not just aging. But they’re also preventable or delayable through aggressive lifestyle intervention.

BRCA2 works alongside BRCA1 as your second major tumor suppressor. Its primary job is to repair double-strand DNA breaks, the most dangerous type of damage your cells can sustain. Think of it as a specialized repair crew that fixes breaks before they can transform into cancer. BRCA2 mutations compromise this repair capacity.

BRCA2 mutations carry a 45-80% lifetime breast cancer risk and 11-17% ovarian cancer risk, plus elevated risks for pancreatic cancer, prostate cancer, and melanoma. About 1 in 500 people carry a BRCA2 mutation overall, though prevalence varies by ancestry. Unlike BRCA1, BRCA2 mutations don’t come with quite as high an ovarian cancer risk, but the breast cancer risk is substantial and the cancer spectrum is broader.

For carriers, this means your cells struggle to repair the most serious DNA damage. Unrepaired breaks can transform into cancer over time. Your immune system catches some of these cells, but not all. Aggressive screening, early detection, and understanding your expanded cancer risk profile across multiple cancer types becomes essential.

F5 encodes Factor V, a protein that’s essential for the first step of blood clotting. When you cut yourself, Factor V helps trigger the cascade that stops the bleeding. This is vital. Without it, you’d bleed to death from minor injuries. With too much, you get clots where they shouldn’t form, blocking blood vessels and causing strokes, DVT (deep vein thrombosis), and pulmonary embolism.

The F5 Leiden mutation, carried by roughly 3-7% of people with European ancestry, makes Factor V resistant to being turned off. This means your blood clots more easily and stays clotted longer than it should. The mutation itself doesn’t guarantee a clot, but it raises your baseline risk. Add oral contraceptives, prolonged immobility (long flights, surgery recovery), pregnancy, or smoking, and your risk jumps substantially.

For you, this means certain situations become higher-risk. A long plane flight without moving isn’t just uncomfortable; it’s a clotting risk. Oral contraceptives weren’t ruled out, but they need closer discussion with your doctor. Surgery recovery requires earlier mobilization. Pregnancy needs monitoring. These aren’t deal-breakers, but they require awareness and planning.

CYP2D6 is one of the most important drug-metabolizing enzymes in your body. It breaks down roughly 25% of all prescription medications, including antidepressants, pain medications, blood pressure drugs, cancer drugs, and antipsychotics. Your CYP2D6 status determines whether medications work as intended, need dose adjustment, or cause side effects.

CYP2D6 comes with multiple variants that make you a fast metabolizer, normal metabolizer, slow metabolizer, or ultra-rapid metabolizer. Roughly 10-15% of people are slow metabolizers, meaning they accumulate drug metabolites and experience side effects at standard doses. Another 1-5% are ultra-rapid metabolizers, needing higher doses for effect. Most common variant carriers are somewhere in between but still deviate from the population average.

For you, this means a standard dose of medication might be wrong for your body. A depression medication that worked perfectly for your friend might make you foggy or nauseous because you metabolize it differently. A pain medication might feel ineffective because you clear it too fast. This isn’t weakness or intolerance. It’s pharmacogenetics. Your genes determine your personalized dose.

HLA-DQ2 is an immune recognition protein. Its job is to present foreign peptides (bits of proteins) to your immune system so it can decide whether to attack or tolerate. In celiac disease, HLA-DQ2 presents gluten peptides in a way that triggers immune cells to attack the small intestine lining. This causes inflammation, damage, nutrient malabsorption, and systemic consequences.

Roughly 30-40% of the population carries HLA-DQ2, but only 2-3% of carriers develop celiac disease. This means having the gene is necessary but not sufficient. Environmental triggers (infections, stress, timing of gluten introduction in infancy) all play a role. But without HLA-DQ2, celiac disease essentially cannot develop.

For you, if you carry HLA-DQ2, it means your immune system has the susceptibility to mount an attack against gluten. You might never develop celiac disease, or symptoms might appear only under stress or after an infection. You might have subclinical inflammation from gluten without obvious digestive symptoms. Understanding your HLA-DQ2 status reframes digestive issues, brain fog, joint pain, skin problems, or fatigue in new ways, because these are sometimes gluten-related even without full celiac diagnosis.